Podravka achieves net profit of €41.1 million

The Podravka Group successfully navigated market uncertainties and consumer spending pressures in the first half of 2026, achieving revenue growth across its Food, Pharmaceuticals, and Agriculture segments. The company reported business revenues of 520.7 million euros for the January-June period, an increase of 8.7 million euros compared to the same period last year. Normalized EBITDA was 89.6 million euros, with a normalized net profit of 41.1 million euros.

Martina Dalić, President of Podravka's Management Board, highlighted the company's continued revenue growth and investments in long-term competitiveness, despite heightened external uncertainties and rising energy prices. She emphasized the strengthening of the food and pharmaceutical segments, alongside ongoing development projects in agriculture.

The Food segment generated sales revenue of 298.9 million euros, a 1.1% increase year-on-year. Belupo, the pharmaceutical division, saw revenues rise by 7.1% to 94 million euros. The Agriculture segment, Podravka Agri, achieved 131.8 million euros in revenue, a 0.5% increase, despite challenges such as falling pig prices and lower milk prices.

“

Usprkos pojačanoj neizvjesnosti iz okruženja i rastu cijena energenata, nastavljamo s rastom prihoda i ulaganjima u dugoročnu konkurentnost – rekla je predsjednica Uprave Podravke Martina Dalić, ističući kako istodobno jačaju prehrambeni i farmaceutski segment te provode razvojne projekte u poljoprivredi.